Skip to main content

Table 1 Synoptic view of the clinical articles

From: Critical appraisal of the role of volumetric modulated arc therapy in the radiation therapy management of breast cancer

Ref. #

Authors

Number of patients

Type of treatment

Median follow-up

Toxicity

[11]

Scorsetti et al.

50

SIB, 40.5Gy to whole breast and 48Gy to tumor bed

12 months

Skin: Max G3 (1 case)

No other toxicity

[12]

De Rose et al.

144

SIB, 40.5Gy to whole breast and 48Gy to tumor bed

37 months

Skin max G3 (1 case)

Lung: max G1 (36 cases)

No other toxicity

[13]

Riou et al.

9

APBI, 40 Gy in 4Gy fractions twice a day over 5 days.

26 months

Acute: Max G1

Late: Max G1

(inclusive of skin, pneumonitis,pain, oedema)

[14]

Kim et al.

31

VMAT with nodal involvement (internal mammary chain)

25.2 months

Late max G2

No cardiac toxicity

[15]

Lauche et al.

HT: 31

VMAT: 42

SIB. Tumor bed: 63.2-63.8Gy; whole breast: 52.2Gy; supraclavicular nodes: 50.4Gy; internal mammary chain nodes: 52.2Gy

Not explicitly reported.

3 months assumption from toxicity assessment statement

Skin: Max G3 (5% of patients, irrespective of technique)

Oesophagus: Max G2 (35-40%)

No lung toxicity

[16]

Fiorentino et al.

16 patients

SIB for synchrounous bilateral breast.

50Gy in 25 fractions to the whole breast, 60Gy to the tumor bed.

24 months

No G3 of any type

Max G2 acute or late skin toxicity

Max G1 acute dysphagia.

  1. HT helical tomotherapy, VMAT volumetric modulated arc therapy, APBI accelerated partial breast irradiation, SIB simultaneous integrated boost